Stifel reaffirms its bullish stance on Elanco Animal Health with a $32 target amid ongoing market analysis.
Stifel reiterated its Buy rating on Elanco Animal Health (ELAN) and set a $32 price target for the stock. The decision reflects continued confidence in the company’s growth prospects and market position in animal health products.
The firm’s prior analysis had highlighted Elanco’s strategic initiatives and financial performance as key drivers for its outlook. No significant changes to consensus estimates or comparable period data were disclosed in the latest update.
Market reaction to the reiterated rating and target was not immediately detailed in the release.